Poliovirus vaccine-inactivated

Vaccines: Sixth Edition

Volumn , Issue , 2012, Pages 573-597

  Vidor, Emmanuel ^a   Plotkin, Stanley A ^b,c  

^a SANOFI PASTEUR   (France)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c WISTAR INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84902042230     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4557-0090-5.00034-3     Document Type: Chapter

References (349)

1. Montagnon B.J., Fanget B., Nicolas A.J. The large-scale cultivation of Vero cells in micro-carrier culture for virus production: preliminary results for killed poliovirus vaccine. Dev Biol Stand 1981, 47:55-64.
2. Dragunsky E.M., Ivanov A.P., Wells V.R., et al. Evaluation of immunogenicity and protective properties of inactivated poliovirus vaccines: a new surrogate method for predicting vaccine efficacy. J Infect Dis 2004, 190:1404-1412.
3. Rezapkin G., Neverov A., Cherkasova E., et al. Repertoire of antibodies against type 1 poliovirus in human sera. J Virol Methods 2010, 169:322-331.
4. Salk J., Cohen H., Fillastre C., et al. Killed poliovirus antigen titration in humans. Dev Biol Stand 1978, 41:119-132.
5. Salk J., van Wezel A.L., Stoeckel P., et al. Theoretical and practical considerations in the application of killed poliovirus vaccine for the control of paralytic poliomyelitis. Dev Biol Stand 1981, 43:181-198.
6. Salk J., Stoeckel P., van Wezel A.L., et al. Antigen content of inactivated poliovirus vaccine for use in a one- or two-dose regimen. Ann Clin Res 1982, 14:204-212.
7. Sutter R.W., Pallansch M.A., Sawyer L.A., et al. Defining surrogate serologic tests with respect to predicting protective vaccine efficacy: poliovirus vaccination. Ann N Y Acad Sci 1995, 754:289-299.
8. Bonnet M.C., Dutta A. World wide experience with inactivated poliovirus vaccine. Vaccine 2008, 26:4978-4983.
9. Stoeckel P., Schlumberger M., Parent G., et al. Use of killed poliovirus vaccine in a routine immunization program in West Africa. Rev Infect Dis 1984, 6(S2):S463-S466.
10. WHO Polio vaccines and polio immunization in the pre-eradication era: WHO position paper. Wkly Epidemiol Rec 2010, 85:213-228.
11. Poliomyelitis Vaccine Evaluation Center Evaluation of 1954 field trials of poliomyelitis vaccine. Introduction. Am J Public Health Nations Health 1955, 45:xii-xiv.
12. Poliomyelitis Vaccine Evaluation Center Evaluation of 1954 field trials of poliomyelitis vaccine, I: plan of study. Am J Public Health Nations Health 1955, 45:1-14.
13. Poliomyelitis Vaccine Evaluation Center Evaluation of 1954 field trials of poliomyelitis vaccine, II: results. Am J Public Health Nations Health 1955, 45:15-48.
14. Poliomyelitis Vaccine Evaluation Center Evaluation of 1954 field trials of poliomyelitis vaccine, III: summary of estimates of effectiveness of vaccine. Am J Public Health Nations Health 1955, 45:49-51.
15. Lambert S.M., Markel H. Making history: Thomas Francis, Jr, MD, and the 1954 Salk poliomyelitis vaccine field trial. Arch Pediatr Adolesc Med 2000, 154:512-517.
16. Plotkin S.A. An end to Manicheism. Public Health Rev 1993, 21:135-138.
17. Landsteiner K., Popper E. Ueberstragung der poliomyelitis acuta auf affen. Z Immunitatsforsch 1909, 2:377-390.
18. Bodian D., Morgan I., Howe H. Differentiation of types of poliomyelitis viruses; the grouping of fourteen strains into three basic immunologic types. Am J Hyg 1949, 49:234-245.
19. Horstman D.M., McCollum R., Mascola A. Viremia in human poliomyelitis. J Exp Med 1954, 99:355-369.
20. Hammon W., Coriell L.L., Wehrle P.F., et al. Evaluation of red cross ?-globulin as a prophylactic agent for poliomyelitis. J Am Med Assoc 1953, 151:1272-1285.
21. Enders J., Weller T., Robbins F. Cultivation of the Lansing strain of poliomyelitis virus in cultures of various human embryonic tissues. Science 1949, 109:85-87.
22. Burke D.S. Lessons learned from the 1954 field trial of poliomyelitis vaccine. Clin Trials 2004, 1:3-5.
23. Beale J. The Development of IPV 1996, Elsevier, Paris.
24. Lépine P. Prophylaxie de la poliomyélite Present et avenir. Bull Org Mond Santé 1955, 13:447-472.
25. van Wezel A.L. Growth of cell-strains and primary cells on micro-carriers in homogeneous culture. Nature 1967, 216:64-65.
26. Montagnon B. Polio and rabies vaccines produced in continuous cell lines: a reality for Vero cell line. Dev Biol Stand 1988, 70:27-47.
27. Paul J.R., Melnick P.J., Barnett V., et al. A survey of neutralizing antibodies to poliomyelitis in Cairo, Egypt. Am J Hyg 1952, 55:402-413.
28. Lebrun A., Cerf J., Gelfand H., et al. Vaccination with the CHAT strain of type I attenuated poliomyelitis virus in Leopoldville, Belgian Congo, I: description of the city, its history of poliomyelitis, and the plan of vaccination campaign. Bull World Health Organ 1960, 22:203-213.
29. Minor P.D. Antigenic structure of picornaviruses. Curr Top Microbiol Immunol 1990, 161:121-154.
30. Plotkin S., Koprowski H., Stokes J. Clinical trials in infants of orally administered attenuated poliomyelitis viruses. Pediatrics 1960, 23:1041-1062.
31. Brodie M., Park W. Active immunization against poliomyelitis. Am J Public Health 1936, 26:119-125.
32. Kolmer J. Vaccination against acute anterior poliomyelitis. Am J Public Health 1936, 26:126-135.
33. Lepine P., Sautter V. Inactivation of viruses by the combined action of two inactivating drugs employed in controlled doses. C R Hedb Seance Acad Sci 1957, 244:2200-2201.
34. Murray R. Standardization licensing and availability of live polio virus vaccine. J Am Med Assoc 1961, 175:843-846.
35. Berkovich S., Pickering J., Kibrick S. Paralytic poliomyelitis in Massachusetts. N Engl J Med 1959, 264:1325-1329.
36. Montagnon B.J., Fanget B., Vincent-Falquet J.C. Industrial-scale production of inactivated poliovirus vaccine prepared by culture of Vero cells on microcarrier. Rev Infect Dis 1984, 6(Suppl. 2):S341-S344.
37. Montagnon B.J., Fanget B., Nicolas A.J. The large-scale cultivation of Vero cells in micro-carrier culture for virus production: preliminary results for killed poliovirus vaccine. Dev Biol Stand 1981, 47:55-64.
38. Montagon B.J., Nicolas A.J., Fanget B., et al. Comparison of sensitivity of Vero cell line versus primary monkey kidney cells in the detection of residual live polio virus during and after inactivation. Dev Biol Stand 1981, 47:151-155.
39. Montagon B.J., Vincent-Falquet J.C., Fanget B. Thousand litre scale microcarrier culture of Vero cells for killed polio virus vaccine.Promising results. Dev Biol Stand 1984, 55:37-42.
40. Duchene M., Peetermans J., D'Hont E., et al. Production of poliovirus vaccines: past, present, and future. Viral Immunol 1990, 3:243-272.
41. Montagnon B.J., Vincent-Falquet J.C., Saluzzo J.F. Experience with Vero cells at Pasteur Merieux Connaught. Dev Biol Stand 1999, 98:137-140.
42. Thomassen Y.E., van Sprang E.N., van der Pol L.A., et al. Multivariate data analysis on historical IPV production data for better process understanding and future improvements. Biotechnol Bioeng 2010, 107:96-104.
43. Horaud F. Viral vaccines and residual cellular DNA. Biologicals 1995, 23:225-228.
44. Melnick J.L. Virus inactivation: lessons from the past. Dev Biol Stand 1990, 75:29-36.
45. Meignier B. Industrial experience with live polio vaccine prepared on the Vero continuous cell line. Dev Biol (Basel) 2001, 106:341-342.
46. Wood D.J., Heath A.B. A WHO collaborative study of immunogenicity assays of inactivated poliovirus vaccines. Biologicals 1995, 23:301-311.
47. Wood D.J., Heath A.B., Kersten G.F., et al. A new WHO International Reference Reagent for use in potency assays of inactivated poliomyelitis vaccine. Biologicals 1997, 25:59-64.
48. Rezapkin G., Dragunsky E., Chumakov K. Improved ELISA test for determination of potency of inactivated poliovirus vaccine (IPV). Biologicals 2005, 33:17-27.
49. Westdijk J., Brugmans D., Martin J., et al. Characterization and standardization of Sabin based inactivated polio vaccine: proposal for a new antigen unit for inactivated polio vaccines. Vaccine 2011, 29:3390-3397.
50. Racaniello V.R. One hundred years of poliovirus pathogenesis. Virology 2006, 344:9-16.
51. Martin J., Crossland G., Wood D.J., et al. Characterization of formaldehyde-inactivated poliovirus preparations made from live-attenuated strains. J Gen Virol 2003, 84:1781-1788.
52. Dragunsky E.M., Ivanov A.P., Wells V.R., et al. Evaluation of immunogenicity and protective properties of inactivated poliovirus vaccines: a new surrogate method for predicting vaccine efficacy. J Infect Dis 2004, 190:1404-1412.
53. Global Polio Eradication Initiative. Accessed on June 1st, 2012. http://www.polioeradication.org/Research/PolioPipeline/No1Summer2008/ImprovingIPV.aspx.
54. Kreeftenberg H., van der Velden T., Kersten G., et al. Technology transfer of Sabin-IPV to new developing country markets. Biologicals 2006, 34(2):155-158.
55. Ferguson M., Wood D.J., Minor P.D. Antigenic structure of poliovirus in inactivated vaccines. J Gen Virol 1993, 74:685-690.
56. Rezapkin G., Martin J., Chumakov K. Analysis of antigenic profiles of inactivated poliovirus vaccine and vaccine-derived polioviruses by block-ELISA method. Biologicals 2005, 33:29-39.
57. Dragunsky E., Chernokhvostova Y., Taffs R., et al. Tg PVR21 mice for testing type-3 oral poliovirus vaccines: role of clinical observation and histological examination vaccine 1997, 15, 1863-6.
58. Kersten G., Hazendonk T., Beuvery C. Antigenic and immunogenic properties of inactivated polio vaccine made from Sabin strains. Vaccine 1999, 17:2059-2066.
59. Herremans T., Reimerink J.H.J., Kimman T.G., et al. Antibody responses to antigenic sites 1 and 3 of serotype 3 poliovirus after vaccination with oral live attenuated or inactivated poliovirus vaccine and after natural exposure. Clin Diag Lab Immunol 2000, 7:40-44.
60. Rezapkin G., Neverov A., Cherkasova E., et al. Repertoire of antibodies against type 1 poliovirus in human sera. J Virol Methods 2010, 169:322-331.
61. Abe S., Tano Y., Ohta Y., et al. Development and clinical evaluation on the enhanced-potency inactivated poliovirus vaccine made from the Sabin strains. Clin Virol 1999, 27:9-28.
62. Tano Y., Shimizu H., Martin J., et al. Antigenic characterization of a formalin-inactivated poliovirus vaccine derived from live-attenuated Sabin strains. Vaccine 2007, 25:7041-7046.
63. Bian C.X., Jiang S.D., Yang J.Y., et al. Effect of 2-phenoxy-ethanol on potency on Sabin inactivated poliomyelitis vaccine and its safety. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 2007, 21:44-46.
64. Che Y.C., Jiang L., Shao C.W. Feasibility study of using Sabin-IPV immunization in post-eradication era in China. Zhongguo Ji Hua Mian Yi 2010, 16:72-75.
65. Verdijk P., Rots N.Y., Bakker W.A.M. Clinical development of a novel inactivated poliomyelitis vaccine based on attenuated Sabin poliovirus strains. Expert Rev Vaccines 2011, 10:635-644.
66. Bakker W.A.M., Thomassen Y.E., van't Oever A.G., et al. Inactivated polio vaccine development for technology transfer using attenuated Sabin poliovirus strains to shift from Salk-IPV to Sabin-IPV. Vaccine 2011, 29:7188-7196.
67. Sawyer L.A., Wood D., Ferguson M., et al. Potency of wild-type or Sabin trivalent inactivated poliovirus vaccine, by enzyme-linked immunosorbent assay using monoclonal antibiotics specific for each antigenic site. Biologicals 1997, 25:299-306.
68. Wood D.J., Heath A.B., Sawyer L.A. A WHO Collaborative study on assays of the antigenic content of inactivated poliovirus vaccines. Biologicals 1995, 23:83-94.
69. Murph J.R., Grose C., McAndrew P., et al. Sabin inactivated trivalent poliovirus vaccine: first clinical trial and seroimmunity survey. Pediatr Infect Dis J 1988, 7:760-765.
70. Doi Y., Abe S., Yamamoto H., et al. Progress with inactivated poliovirus vaccines derived from the Sabin strains. Dev Biol (Basel) 2001, 105:163-169.
71. Eighth WHO/UNICEF consultation with OPV/IPV manufacturers and NRAs in Geneva WHO/HQ 2009, (Accessed November 2011). http://www.who.int/immunization_standards/vaccine_quality/ipvopv_summary3dec09.pdf.
72. Liao G., Li R., Li C., et al. Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains: A phase II, randomized, positive-controlled trial. Journal of Infectious Diseases 2012, 205:237-243.
73. Horie H., Yoshida H., Matsuura K., et al. Isolation of vaccine-derived type 1 polioviruses displaying similar properties to virulent wild strain Mahoney from sewage in Japan. J Med Virol 2002, 68:445-451.
74. Ehrenfeld E., Modlin J., Chumakov K. Future of polio vaccines. Expert Rev Vaccines 2009, 8:899-905.
75. Global Post-eradication IPV Supply and Demand Assessment: Integrated Findings 2009, (Accessed November 2011). http://www.polioeradication.org/content/general/March%202009%20OW%20IPV%20Effort%20Report.pdf.
76. The supply landscape and economics of ipv-containing combination vaccines: key findings 2010, (Accessed November 2011). http://www.polioeradication.org/Portals/0/Document/Resources/SupplyLandscapeEconomics.09.06.2010.pdfs.
77. Salk J. One-dose immunization against paralytic poliomyelitis using a non infectious vaccine. Rev Infect Dis 1984, 6(Suppl. 2):S444-S450.
78. Salk J., Cohen H., Fillastre C., et al. Killed poliovirus antigen titration in humans. Dev Biol Stand 1978, 41:119-132.
79. Salk J., van Wezel A.L., Stoeckel P., et al. Theoretical and practical considerations in the application of killed poliovirus vaccine for the control of paralytic poliomyelitis. Dev Biol Stand 1981, 43:181-198.
80. Salk J., Stoeckel P., van Wezel A.L., et al. Antigen content of inactivated poliovirus vaccine for use in a one- or two-dose regimen. Ann Clin Res 1982, 14:204-212.
81. Mellander L., Bottiger M., Hanson L.A., et al. Avidity and titers of the antibody response to two inactivated poliovirus vaccines with different antigen content. Acta Paediatr 1993, 82:552-556.
82. Knuf M., Vetter V., Celzo F., et al. Repeated administration of a reduced-antigen content dipththeria-tetanus-acellular pertussis and poliomyelitis vaccine (dTpa-IPV; Boostrix IPV). Hum Vaccin 2010, 6:554-561.
83. Larnaudie S., Guiso N., Baptiste C., et al. Humoral immunity of dTap-IPV vaccine (Repevax) administered one month after dT-IPV vaccine (Revaxis) in adults with unknown vaccination history. Hum Vaccin 2010, 6:829-834.
84. Beytout J., Launay O., Guiso N., et al. Safety of Tadp-IPV given one month after Td-IPV booster in healthy young adults: a placebo-controlled trial. Hum Vaccin 2009, 5:315-321.
85. Hässelbarth A. Effect of polymyxin B on the replication of poliovirus in cell cultures. Med Microbiol Immunol 1972, 157:239-243.
86. McBean A.M., Thoms M.L., Albrecht P., et al. Field staff and coordinating committee. Am J Epidemiol 1988, 128:615-628.
87. Cutler J.C., Lesesne L., Lit M., et al. Use of poliomyelitis virus vaccine in light mineral oil adjuvant in a community immunization program and report of reactions encountered. J Allergy 1962, 33:193-209.
88. Henneberg G., Drescher J., Godgluck G., et al. Immunogenic activity of aqueous and aluminum oxide adsorbed poliovirus vaccine in Macata mulata. Am J Hyg 1962, 75:44-55.
89. Relyveld E., Martin R., Raynaud M., et al. Le phosphate de calcium comme adjuvant dans les vaccinations chez l'homme. Ann Inst Pasteur 1969, 116:300-326.
90. Ivanov A.P., Dragunsky E.M., Chumakov K.M. 1,25-dihydroxyvitamin D3 enhances systemic and mucosal immune responses to inactivated poliovirus vaccine in mice. J Infect Dis 2006, 193:598-600.
91. Yang C., Shi H., Zhou J., et al. CpG oligooxynucleotides are a potent adjuvant for an inactivated polio vaccine produced from Sabin strains of poliovirus. Vaccine 2009, 27:6558-6563.
92. Ghendon Y., Markushin S., Koptiaeva I., et al. Chitosan as an adjuvant for poliovaccine. J Med Virol 2011, 83:847-852.
93. Sawyer L.A., McInnis J., Patel A., et al. Deleterious effect of thimerosal on the potency of inactivated poliovirus vaccine. Vaccine 1994, 12:851-856.
94. Sutter R.W., Pallansch M.A., Sawyer L.A., et al. Defining surrogate serologic tests with respect to predicting protective vaccine efficacy: poliovirus vaccination. Ann N Y Acad Sci 1995, 754:289-299.
95. WHO Guidelines for WHO/EPI collaborative studies on poliomyelitis. Standard procedure for determining immunity to poliovirus using the microneutralization test 1993, WHO/EPI/GEN 93.9, WHO, Geneva, Switzerland.
96. Boone E.J., Albrecht P. Conventional and enhanced plaque neutralization assay for polio antibody. J Virol Methods 1983, 6:193-202.
97. Albrecht P., Enterline J.C., Boone E.J., et al. Poliovirus and polio antibody assay in HEp-2 and Vero cell cultures. J Biol Stand 1983, 11:91-97.
98. Albrecht P., van Sleenis G., van Wezel A.L., et al. Standardization of poliovirus neutralizing antibody tests. Rev Infect Dis 1984, 6(S2):S540-S544.
99. Wood D.J., Heath A.B. Comparability of poliovirus neutralizing antibody tests. Biologicals 1992, 20:293-300.
100. Wood D.J., Heath A.B. The second international standard for anti-poliovirus sera types 1, 2 and 3. Biologicals 1992, 20:203-211.
101. Vidor E., Caudrelier P., Plotkin S.A. The place of DTP/eIPV vaccine in routine paediatric vaccination. Rev Med Virol 1994, 4:261-277.
102. Vidor E., Meschievitz C., Plotkin S.A. Fifteen years of experience with Vero-produced enhanced potency inactivated poliovirus vaccine. Pediatr Infect Dis J 1997, 16:312-322.
103. Poliovirus vaccine inactivated IPOL,. (Accessed in November 2011). https://www.vaccineshoppe.com/image.cfm?doc_id=5984&image_type=product_pdf.
104. Bonnet M.C., Dutta A. World wide experience with inactivated poliovirus vaccine. Vaccine 2008, 26:4978-4983.
105. Juhela S., Hyoty H., Lonnrot M., et al. Enterovirus infections and enterovirus specific T-cell responses in infancy. J Med Virol 1998, 54:226-232.
106. Glezen W.P. Effect of maternal antibodies on the infant immune response. Vaccine 2003, 21:3389-3392.
107. Sormunen H., Stenvik M., Eskola J., et al. Age- and dose-interval-dependent antibody responses to inactivated poliovirus vaccine. J Med Virol 2001, 63:305-310.
108. Hovi T. Inactivated poliovirus vaccine and the final stages of poliovirus eradication. Vaccine 2001, 19:2268-2272.
109. Singh J., Ravi R.N., Dutta A.K., et al. Immunogenicity of enhanced potency inactivated polio vaccine. Indian Pediatr 1992, 29:1353-1356.
110. Kok P.W., Leeuwenburg J., Tukei P., et al. Serological and virological assessment of oral and inactivated poliovirus vaccines in a rural population in Kenya. Bull World Health Organ 1992, 70:93-103.
111. Linder N., Handsher R., German B., et al. Controlled trial of immune response of preterm infants to recombinant hepatitis B and inactivated poliovirus vaccines administered simultaneously shortly after birth. Arch Dis Child Fetal Neonatal Ed 2000, 83:F24-F27.
112. WHO Collaborative Study Group on Oral and Inactivated Poliovirus Vaccines Combined immunization of infants with oral and inactivated poliovirus vaccines: results of a randomized trial in the Gambia, Oman, and Thailand. Bull World Health Organ 1996, 74:253-268.
113. Sutter R.W., Suleiman A.J., Malankar P.G., et al. Sequential use of inactivated poliovirus vaccine followed by oral poliovirus vaccine in Oman. J Infect Dis 1997, 175(Suppl. 1):S235-S240.
114. Simoes E.A., Padmini B., Steinhoff M.C., et al. Antibody response of infants to two doses of inactivated poliovirus vaccine of enhanced potency. Am J Dis Child 1985, 139:977-980.
115. Simoes E.A., John T.J. The antibody response of seronegative infants to inactivated poliovirus vaccine of enhanced potency. J Biol Stand 1986, 14:127-131.
116. Swartz T.A., Handsher R., Stoeckel P., et al. Immunologic memory induced at birth by immunization with inactivated polio vaccine in a reduced schedule. Eur J Epidemiol 1989, 5:143-145.
117. Hovi T., Stenvik M., Agboatwalla M. Effect of administering oral and inactivated polio vaccines immediately after birth. Eur J Clin Microbiol Infect Dis 1999, 18:526-528.
118. Jain P.K., Dutta A.K., Nangia S., et al. Seroconversion following killed polio vaccine in neonates. Indian J Pediatr 1997, 64:511-515.
119. Ruuskanen O., Viljanen M., Salmi T.T., et al. DTP and DTP-inactivated polio vaccines: comparison of adverse reactions and IgG, IgM and IgA antibody responses to DTP. Acta Paediatr Scand 1980, 69:177-182.
120. White C., Halperin S., Scheifele D. Pediatric combined formulation DTaP-IPV/Hib vaccine. Expert Rev Vaccines 2009, 8:831-840.
121. Mallet E., Belohradsky B., Lagos R., et al. A liquid hexavalent combined vaccine against diphtheria, tetanus, pertussis, poliomyelitis, Haemophilus influenzae type B and hepatitis B: review of immunogenicity and safety. Vaccine 2004, 22:1343-1357.
122. Dhillon S. DTaP-HBV-IPV/Hib vaccine (Infanrix hexa): a review of its use as primary series and booster vaccination. Drugs 2010, 70:1021-1058.
123. Plotkin S.A., Liese L., Madhi S.A., et al. A DTaP-IPV//PRP T vaccine (Pentaxim™): a review of 16 years' clinical experience. Expert Rev Vaccines 2011, 10:981-1005.
124. Quiambao B., Meeren van der O., Kolhe D., et al. A randomized, dose-ranging assessment of the immunogenicity and safety of a booster dose of a combined diphtheria-tetanus-whole cell pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b (DTPw-HBV-IPV/Hib) vaccine vs. Human Vaccine 2012, 8:1-8. co-administration of DTPw-HBV/Hib and IPV vaccines in 12 to 24 months old Filipino toddlers.
125. Black S., Greenberg D.P. A combined diphtheria, tetanus, five-component acellular pertussis, poliovirus and Haemophilus influenzae type b vaccine. Expert Rev Vaccines 2005, 4:793-805.
126. Zepp F., Knuf M., Heininger U., et al. Safety, reactogenicity and immunogenicity of a combined hexavalent tetanus, diphtheria, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate vaccine, for primary immunization of infants. Vaccine 2004, 22:2226-2233.
127. Lee S.Y., Hwang H.S., Kim J.H., et al. Immunogenicity and safety of a combined diphtheria, tetanus, acellular pertussis and inactivated poliovirus vaccine (DTaP-IPV) compared to separate administration of standalone DTaP and IPV vaccines: a randomized, controlled study in infants in the Republic of Korea. Vaccine 2011, 29:1551-1557.
128. Lagos R., Kotloff K., Hoffenbach A., et al. Clinical acceptability and immunogenicity of a pentavalent parenteral combination vaccine containing diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis ad Haemophilus influenzae type b conjugate antigens in two-, four- and six-month-old Chilean infants. Pediatr Infect Dis J 1998, 17:294-304.
129. Yeh S., Ward J.I., Partridge S., et al. Safety and immunogenicity of a pentavalent diphtheria, tetanus, pertussis, hepatitis B and polio combination vaccine in infants. Ped Infect Dis J 2001, 20:973-980.
130. Pichichero M., Bernstein H., Blatter M.M., et al. Immunogenicity and safety of a combination diphtheria, tetanus toxoid, acellular pertussis, hepatitis B, and inactivated poliovirus vaccine coadministered with a 7-valent pneumococcal conjugate vaccine and a Haemophilus influenzae type b conjugate vaccine. J Pediatr 2007, 151:43-49.
131. Meriste S., Lutsar I., Tamm E., et al. Safety and immunogenicity of a primary course and booster dose of a combined diphtheria, tetanus, acellular pertussis, hepatitis B and inactivated poliovirus vaccine. Scand J Infect Dis 2006, 38:350-356.
132. Grimprel E., von Sonnenburg F., Sanger R., et al. Combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and polio vaccine (dTpa-IPV) for booster vaccination of adults. Vaccine 2005, 23:3657-3667.
133. Southern J., Andrews N., Burrage M., et al. Immunogenicity and reactogenicity of combined acellular pertussis/tetanus/low dose diphtheria vaccines given as booster to UK teenagers. Vaccine 2005, 23:3829-3835.
134. Laroche P., Barrand M., Wood S., et al. The immunogenicity and safety of a new combined diphtheria, tetanus and poliomyelitis booster vaccine (Td-eIPV). Infection 1999, 27:49-60.
135. Jacquet J.M., Begue P., Grimprel E., et al. Safety and immunogenicity of a combined DTPa-IPV vaccine administered as a booster from 4 years of age: a review. Vaccine 2006, 24:2400-2448.
136. Kaml M., Weiskirchner I., Keller M., et al. Booster vaccination in the elderly: their success depends on the vaccine type applied earlier in life as well as on pre-vaccination antibody titers. Vaccine 2006, 24:6808-6811.
137. Salk J. Studies in human subjects on active immunization against poliomyelitis, I. a preliminary report of experiments in progress. J Am Med Assoc 1953, 151:1081-1098.
138. Salk J. Recent studies on in immunization against poliomyelitis. Pediatrics 1953, 12:471-482.
139. von Magnus H., von Magnus P., Petersen I., et al. Polio vaccination in Denmark in April-June 1955, I: the production of formalinized poliovaccine and preliminary results. Dan Med Bull 1955, 2:226-233.
140. Sigurdsson B., Gudnadottir M., Petursson G. Response to poliomyelitis vaccination. Lancet 1958, 370-371.
141. Connolly J.H., Dick G.W. Antibody responses following intradermal or oral administration of formalinised poliomyelitis vaccine. Lancet 1958, 333-336.
142. Slonim D., Svandova E., Strand P., et al. History of poliomyelitis in the Czech Republic-Part III. Cent Eur J Public Health 1995, 3:124-126.
143. Skovranek V., Radkovsky J., Roudny J., et al. Vaccination against poliomyelitis in Czechoslovakia in 1957, II. evaluation of morbidity following vaccination. J Hyg Epidemiol Microb Immunol 1958, 2:469-477.
144. Lipson M.J., Carver D.H., Eleff M.G., et al. Antibody response to poliomyelitis vaccine administered by jet injection. Am J Public Health Nations Health 1958, 48:599-603.
145. Hingson R.A., Davis H.S., Bloomfield R.A., et al. Mass inoculation of the Salk polio vaccine with the multiple dose jet injector. GP 1957, 15:94-96.
146. Samuel B., Cherian T., Sridharan G., et al. Immune response to intradermally injected inactivated poliovirus vaccine. Lancet 1991, 338:343-344.
147. Samuel B., Cherian T., Rajasingh J., et al. Immune response of infants to inactivated poliovirus vaccine injected intradermally. Vaccine 1992, 10:135.
148. Nirmal S., Cherian T., Samuel B.U., et al. Immune response of infants to fractional doses of intradermally administered inactivated poliovirus vaccine. Vaccine 1998, 16:928-931.
149. Resik S., Tejeda A., Lago P.M., et al. Randomised controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle-free device in Cuba. J Infect Dis 2010, 201:1344-1352.
150. Mohammed A.J., AlAwaidy S., Bawikar S., et al. Fractional doses of inactivated poliovirus vaccine in Oman. N Engl J Med 2010, 362:2351-2359.
151. Carlos J., Vidor E., Bonnet M.C. Immunogenicity and safety profile of inactivated polio vaccine (Imovax Polio™) administered at a fractional dose intradermally in comparison with inactivated polio vaccine (Imovax Polio™) administered at a full dose intramuscularly in the Philippines using the epi schedule. Int J Infect Dis 2012, 116:e110-e116.
152. Estivariz C., Jafari H., Sutter R.W., et al. Immunogenicity of supplemental doses of poliovirus vaccine for children age 6-9 months in Moradabad, India: a community-based, randomised controlled trial. Lancet Infect Dis 2012, 12:128-135.
153. Sutter R. Personal communication.
154. Nelson K.S., Janssen J.M., Troy S.B., et al. Intradermal fractional dose inactivated polio vaccine: A review of literature. Vaccine 2012, 30:121-125.
155. WHO Collaborative Study Group on Oral and Inactivated Poliovirus Vaccines Combined immunization of infants with oral and inactivated poliovirus vaccines: results of a randomized trial in the Gambia, Oman, and Thailand. J Infect Dis 1997, 175(Suppl. 1):S215-S227.
156. Krishnan R., Jadhav M., John T.J. Efficacy of inactivated poliovirus vaccine in India. Bull World Health Organ 1983, 61:689-692.
157. Gylca R., Gylca V., Benes O., et al. A new DTPa-HBV-IPV vaccine co-administered with Hib, compared to a commercially available DTPw-IPV/Hib vaccine co-administered with HBV, given at 6, 10 and 14 weeks following HBV at birth. Vaccine 2000, 19:825-833.
158. Hussey G., Malan H., Hughes J., et al. 1998, Aventis Pasteur Study HIT40498. Data in file.
159. Capeding M.R. 1999, Aventis Pasteur study EUV07199/HE9810. Data in File.
160. Cuba IPV Study Collaborative Group Randomized, placebo-controlled trial of inactivated poliovirus vaccine in Cuba. N Engl J Med 2007, 356:1536-1544.
161. Hussey G. 2005, Sanofi Pasteur Study A3R25 and A3R38. Data in file.
162. Capeding R.M., Cadorna-Carlos J., Book-Montellano M., et al. Immunogenicity and safety of a DTaP-IPV//PRP-T combination vaccine given with hepatitis B vaccine; a randomized open-label trial. Bull World Health Organ 2008, 86:443-451.
163. Dayan G.H., Thorley M., Yamamura Y., et al. Serologic response to inactivated poliovirus vaccine: a randomized clinical trial comparing 2 vaccination schedules in Puerto Rico. J Infect Dis 2007, 195:12-20.
164. Madhi S.A., Cutland C., Jones S., et al. Immunogenicity and safety of an acellular pertussis, diphtheria, tetanus, inactivated poliovirus, Hib-conjugate combined vaccine (Pentaxim™) and monovalent hepatitis B vaccine at 6, 10 and 14 months of age in infants in South Africa. S Afr Med J 2011, 101:126-131.
165. Dutta A.K., Verghese V.P., Pemde H.K., et al. Immunogenicity and safety of a pentavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b conjugate combination vaccine (Pentaxim™) with hepatitis B vaccine. Indian Pediatr 2009, 46:975-982.
166. Madhi S., Mitha I., Santos Lima E. Immunogenicity and safety of an investigational fully liquid hexavalent DTaP IPV Hep B PRP-T combined vaccine versus DTwP//Hib, Hepatitis B and OPV licensed vaccines at 6, 10, and 14 weeks of age in healthy South African infants. Pediatr Infect Dis J 2011, 30:458-465.
167. Centers for Disease Control, Prevention Poliomyelitis prevention in the United States: introduction of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1997, 46(RR-3).
168. Halsey N., Blatter M., Bader G., et al. Inactivated poliovirus vaccine alone or sequential inactivated and oral poliovirus vaccine in two-, four- and six-month-old infants with combination Haemophilus influenzae type b/hepatitis B vaccine. Pediatr Infect Dis J 1997, 16:675-679.
169. Modlin J.F., Halsey N., Thoms M.L., et al. The Baltimore Area Polio Vaccine Study Group. Humoral and mucosal immunity in infants induced by three sequential inactivated poliovirus vaccine-live attenuated oral poliovirus vaccine immunization schedules. J Infect Dis 1997, 175(Suppl. 1):S228-S234.
170. Asturias E.J., Dueger E.L., Omer S.B., et al. Randomized trial of inactivated and live polio vaccine schedules in Guatemalan infants. J Infect Dis 2007, 196:692-698.
171. Lasch E.E., Abed Y., Gerichter C.B., et al. Results of a program successfully combining live and killed polio vaccines. Isr J Med Sci 1983, 19:1021-1023.
172. Ramsay M.E., Begg N.T., Gandhi J., et al. Antibody response and viral excretion after live polio vaccine or a combined schedule of live and inactivated polio vaccines. Pediatr Infect Dis J 1994, 13:1117-1121.
173. Strebel P., Ion-Nedelcu N., Baughman A.L., et al. Intramuscular injections within 30 days of immunization with oral poliovirus vaccine-a risk factor for vaccine-associated paralytic poliomyelitis. N Engl J Med 1995, 332:500-506.
174. Ion-Nedelcu N., Strebel P., Toma F., et al. Sequential and combined use of inactivated and oral poliovirus vaccines: Dolj District, Romania, 1992-1994. J Infect Dis 1997, 175:S241-S246.
175. Moriniere B.J., van Loon F.P., Rhodes P.H., et al. Immunogenicity of a supplemental dose of oral versus inactivated poliovirus vaccine. Lancet 1993, 341:1545-1550. [see comments].
176. Parent du Chatelet I., Merchant A.T., Fisher-Hoch S., et al. Serological response and poliovirus excretion following different combined oral and inactivated poliovirus vaccines immunization schedules. Vaccine 2003, 21:1710-1718.
177. Sutter R., Suleiman A.J.S., Malankar P., et al. Trial of a supplemental dose of four poliovirus vaccines. N Engl J Med 2000, 343:767-773.
178. Herremans T.M.P.T., Reimerink J.H.J., Buisman A.M., et al. Induction of mucosal immunity by inactivated poliovirus vaccine is dependent on previous mucosal contact with live virus. J Immunol 1999, 162:5011-5018.
179. Adenyi-Jones S.C.A., Faden H., Ferdon M.B., et al. Systemic and local immune responses to enhanced-potency inactivated poliovirus vaccine in premature and term infants. J Pediatr 1992, 120:686-689.
180. Linder N., Yaron M., Handsher R., et al. Early immunization with inactivated poliovirus vaccine in premature infants. J Pediatr 1995, 127:128-130.
181. Sikora J.P., Chlebna-Sokol D. Seroconversion after vaccination against pertussis, Haemophilus influenzae type b and poliomyelitis in preterm infants. Przegl Lek 2003, 60:699-703.
182. Klein N.P., Gans H.A., Sung P., et al. Preterm infants' T cell responses to inactivated poliovirus vaccine. J Infect Dis 2010, 201:214-222.
183. Vasquez L., Garcia F., Ruttimann R., et al. Immunogenicity and reactogenicity of DTPa-HBV-IPV/Hib vaccine as primary and booster vaccination on low-birth-weight premature infants. Acta Paediatr 2008, 97:1243-1249.
184. Slack M.H., Cade S., Schapira D., et al. DT5aP-Hib-IPV and MCC vaccines: preterm infants' responses to accelerated immunization. Arch Dis Child 2005, 90:338-341.
185. O'Shea T.M., Dillard R.G., Gillis D.C., et al. Low rate of response to enhanced inactivated polio vaccine in preterm infants with chronic illness. Clin Res Reg Aff 1993, 10:49-57.
186. Barbi M., Bardare M., Luraschi C., et al. Antibody response to inactivated polio vaccine (E-IPV) in children born to HIV positive mothers. Eur J Epidemiol 1992, 8:211-216.
187. Varon D., Handsher R., Dardik R., et al. Response of hemophilic patients to poliovirus vaccination: correlation with HIV serology and with immunological parameters. J Med Virol 1993, 40:91-95.
188. Sipila R., Hortling L., Hovi T. Good seroresponse to enhanced-potency inactivated poliovirus vaccine in patients on chronic dialysis. Nephrol Dial Transplant 1990, 5:352-355.
189. Engelhard D., Handsher R., Naparstek E., et al. Immune response to polio vaccination in bone marrow transplant recipients. Bone Marrow Transplant 1991, 8:295-300.
190. Ljungman P., Duraj V., Magnius L. Response to immunization against polio after allogeneic marrow transplantation. Bone Marrow Transplant 1991, 7:89-93.
191. Ljungman P., Aschan J., Gustafsson B., et al. Long-term immunity to poliovirus after vaccination of allogeneic stem cell transplant recipients. Bone Marrow Transplant 2004, 34:1067-1069.
192. Ogra P.L., Karzon D., Righthand F., et al. Immunoglobulin response in serum and secretions after immunization with live and inactivated polio vaccine and natural infection. N Engl J Med 1968, 279:893-900.
193. Zhaori G., Sun M., Faden H.S., et al. Nasopharyngeal secretory antibody response to poliovirus type 3 virion proteins exhibit different specificities after immunization with live or inactivated poliovirus vaccines. J Infect Dis 1989, 159:1018-1024.
194. Faden H., Duffy L. Effect of concurrent viral infection on systemic and local antibody responses to live attenuated and enhanced-potency inactivated poliovirus vaccines. Am J Dis Child 1992, 146:1320-1323.
195. Faden H., Modlin J., Thoms M.L., et al. Comparative evaluation of immunization with live attenuated and enhanced-potency inactivated trivalent poliovirus vaccines in childhood: systemic and local immune responses. J Infect Dis 1990, 162:1291-1297.
196. Onorato I.M., Modlin J.F., McBean A.M., et al. Mucosal immunity induced by enhanced-potency inactivated and oral polio vaccines. J Infect Dis 1991, 163:1-6.
197. Hanson L.A., Carlsson B., Jalil F., et al. Different secretory IgA antibody responses after immunization with inactivated and live poliovirus vaccines. Rev Infect Dis 1984, 6(Suppl. 2):S356-S360.
198. Fox J.P., Gelfand H.M., LeBlanc D.R., et al. The influence of natural and artificially induced immunity on alimentary infections with poliovirus. Am J Public Health 1958, 48:1181-1192.
199. Horstman D.M., Paul J.R., Melnick J.L., et al. Infection induced by oral administration of attenuated poliovirus to persons possessing homotypic antibody. J Exp Med 1957, 105:159-177.
200. David D., Lipson M., Carver D., et al. The degree and duration of poliomyelitis virus excretion among vaccinated household contacts of clinical cases of poliomyelitis. Pediatrics 1958, 22:33-40.
201. Gelfand H.M., LeBlanc D.R., Potash L., et al. Studies on the development of natural immunity to poliomyelitis in Louisiana, IV: natural infections with polioviruses following immunization with a formalin-inactivated vaccine. Am J Hyg 1959, 70:312-327.
202. Howe H.A., O'Leary W., Bender W., et al. Day-by-day response of vaccinated chimpanzees to poliomyelitis infection. Am J Public Health 1956, 47:871-875.
203. Craig D.E., Brown G.C. The relationship between poliomyelitis antibody and virus excretion from the pharynx and anus of orally infected monkeys. Am J Hyg 1959, 69:1-12.
204. Selvakumar R., John T.J. Intestinal immunity induced by inactivated poliovirus vaccine. Vaccine 1987, 5:141.
205. Marine W.M., Chin T.D.Y., Gravelle C.R. Limitation of fecal and pharyngeal poliovirus excretion in Salk-vaccinated children. Am J Hyg 1962, 76:173-195.
206. Swartz T.A., Green M.S., Handscher R., et al. Intestinal immunity following a combined enhanced inactivated polio vaccine/oral polio vaccine programme in Israel. Vaccine 2008, 26:1083-1090.
207. Ghendon Y., Robertson S.E. Interrupting the transmission of wild polioviruses with vaccines: immunological considerations. Bull World Health Organ 1994, 72:973-983.
208. Samoilovich E., Roivainen M., Titov L.P., et al. Serotype-specific mucosal immune response and subsequent poliovirus replication in vaccinated children. J Med Virol 2003, 71:274-280.
209. Laassri M., Lottenbach K., Belshe R., et al. Effect of different vaccination schedules on excretion of oral poliovirus vaccine strains. J Infect Dis 2005, 192:2092-2098.
210. Minor P.D. The molecular biology of poliovaccines. J Gen Virol 1992, 73:3065-3077.
211. Macadam A.J., Arnold C., Howlett J., et al. Reversion of the attenuated and temperature-sensitive phenotypes of the Sabin type 3 strain of poliovirus in vaccinees. Virology 1989, 172:408-414.
212. Chumakov K.M., Powers L.B., Noonan K.E., et al. Correlation between amount of virus with altered nucleotide sequence and the monkey test for acceptability of oral poliovirus vaccine. Proc Natl Acad Sci U S A 1991, 88:199-203.
213. Abraham R., Minor P., Dunn G., et al. Shedding of virulent poliovirus revertants during immunization with oral poliovirus vaccine after prior immunization with inactivated polio vaccine. J Infect Dis 1993, 168:1105-1109.
214. Ogra P.L., Faden H.S., Abraham R., et al. Effect of prior immunity on the shedding of virulent revertant virus in feces after oral immunization with live attenuated poliovirus vaccines. J Infect Dis 1991, 164:191-194.
215. Murdin A.D., Barreto L., Plotkin S.A. Inactivated poliovirus vaccine: past and present experience. Vaccine 1996, 14:735-746.
216. Minor P.D., Dunn G., Ramsay M.E., et al. Effect of different immunisation schedules on the excretion and reversion of oral poliovaccine strains. J Med Virol 2005, 75:153-160.
217. Laassri M., Lottenbach K., Belshe R., et al. Analysis of reversions in the 5?-untranslated region of attenuated poliovirus after sequential administration of inactivated and oral poliovirus vaccines. J Infect Dis 2006, 193:1344-1349.
218. Francis T., Korns R., Voight R., et al. Am J Public Health Nations Health 1955, 45(5 pt2):1-63.
219. Melnick J.L., Benyeh-Melnick M., Peña R., et al. Effectiveness of Salk vaccine. Analysis of virologically confirmed cases of paralytic and nonparalytic poliomyelitis. J Am Med Assoc 1961, 175:1159-1162.
220. Stoeckel P., Schlumberger M., Parent G., et al. Use of killed poliovirus vaccine in a routine immunization program in West Africa. Rev Infect Dis 1984, 6(S2):S463-S466.
221. Sanofi Pasteur, Kolda area intervention study. Data in file.
222. CDC Paralytic poliomyelitis-Senegal, 1986-1987: update on the N-IPV efficacy study. MMWR 1988, 37:257-259.
223. John T. Poliovirus vaccine and poliomyelitis control in India 1992, [abstract], New Delhi.
224. Varughese P.V., Carter A.O., Acres S.E., et al. Eradication of indigenous poliomyelitis in Canada: impact of immunization strategies. Can J Public Health 1989, 80:363-368.
225. Plotkin S.A. Correlates of protection induced by vaccination. Clin Vaccine Immunol 2010, 17:1055-1065.
226. Stickle G. Observed and expected poliomyelitis in the United States, 1958-1961. Am J Public Health 1964, 54:222-229.
227. Chin T.D. Immunity induced by inactivated poliovirus vaccine and excretion of virus. Rev Infect Dis 1984, 6(Suppl. 2):S369-S370.
228. Hofman B. Poliomyelitis in the Netherlands before and after vaccination with inactivated poliovaccine. J Hyg 1967, 65:547-557.
229. Poliovirus infections. Red Book Report of the Committee of Infectious Diseases 1997, 424-433. American Academy of Pediatrics, Elk Grove, IL. 24th ed. G. Peter, C. Hall, N. Halsey (Eds.).
230. Bijkerk H. Poliomyelitis in the Netherlands. Dev Biol Stand 1981, 47:233-240.
231. Bijkerk H. Poliomyelitis epidemic in the Netherlands, 1978. Dev Biol Stand 1979, 43:195-206.
232. Oostvogel P.M., van Wijngaarden J.K., van der Avoort H.G., et al. Poliomyelitis outbreak in an unvaccinated community in The Netherlands, 1992-93. Lancet 1994, 344:665-670. [see comments].
233. CDC Epidemiological notes and reports: follow-up on poliomyelitis-United States, Canada, Netherlands, 1979. MMWR 1979, 28:345.
234. CDC Lack of evidence for wild poliovirus circulation-United States, 1993. MMWR 1995, 43:957-959.
235. Rumke H.C. Vaccination against polio. Inactivated polio vaccine used in The Netherlands and Burkina Faso. Trop Geogr Med 1993, 45:202-205.
236. Oostvogel P.M., Rumke H.C., Conyn-Van Spaendonck M.A., et al. Poliovirus circulation among schoolchildren during the early phase of the 1992-1993 poliomyelitis outbreak in The Netherlands. J Infect Dis 2001, 184:1451-1455.
237. Gary H.E., Smith J.B., Jenks J., et al. Failure to detect infection by oral polio vaccine virus following natural exposure among inactivated polio vaccine recipients. Epidemiol Infect 2008, 136:180-183.
238. Mueller J.E., Bessaud M., Huang Q.S., et al. Environmental poliovirus surveillance during oral poliovirus vaccine and inactivated poliovirus vaccine use in Cordoba province, Argentina. Appl Environ Microbiol 2009, 75:1395-1401.
239. Troy S.B., Ferreyra-Reyes L., Huang C.H., et al. Use of a novel real-time PCR assay to detect oral polio vaccine shedding and reversion in stool and sewage samples after a Mexican national immunization day. J Clin Microbiol 2011, 49:1777-1783.
240. Hird T.R., Grassly N.C. Systematic review of mucosal immunity induced by oral and inactivated poliovirus vaccines against virus shedding following oral poliovirus challenge. PLos Pathogens 2012, 8:e1002599.
241. Bottiger M. Polio immunity to killed vaccine: an 18-year follow-up. Vaccine 1990, 8:443-445.
242. Taranger J., Trollfors B., Knutsson N., et al. Vaccination of infants with a four-dose and a three-dose vaccination schedule. Vaccine 2000, 18:884-891.
243. Faden H., Duffy L., Sun M., et al. Long-term immunity to poliovirus in children immunized with live attenuated and enhanced-potency inactivated trivalent poliovirus vaccines. J Infect Dis 1993, 168:452-454.
244. Swartz T.A., Roumiantzeff M., Peyron L., et al. Use of a combined DTP-polio vaccine in a reduced schedule. Dev Biol Stand 1986, 65:159-166.
245. Carlsson R.M., Claesson B.A., Fagerlund E., et al. Antibody persistence in 5 year old children who received a pentavalent vaccine in infancy. Pediatr Infect Dis J 2002, 21:535-541.
246. Black S., Friedland L.R., Ensor K., et al. Diphtheria-tetanus-acellular pertussis and inactivated poliovirus vaccines given separately or combined for booster dosing at 4-6 years of age. Pediatr Infect Dis J 2008, 27:341-346.
247. Kitchin N., Southern J., Morris R., et al. Antibody persistence in UK pre-school children who received a primary series of an acellular pertussis-containing pentavalent infant vaccine given concomitantly with meningococcal group C conjugate vaccine, and response to a booster dose of an acellular pertussis-containing quadrivalent vaccine. Vaccine 2009, 27:5096-5102.
248. Langue J., Matisse N., Pacoret P., et al. Persistence of antibodies at 5-6 years of age for children who received a primary series vaccination with a pentavalent whole-cell pertussis vaccine and a first booster with a pentavalent acellular pertussis vaccine: immunogenicity and tolerance of second booster with a tetravalent acellular vaccine at 5-6 years of age. Vaccine 2004, 22:1406-1414.
249. Mallet E., Matisse N., Mathieu N., et al. Antibody persistence against diphtheria, tetanus, pertussis, poliomyelitis and Haemophilus influenzae type b (Hib) in 5-6 year-old children after primary vaccination and first booster with a pentavalent combined acellular pertussis vaccine: immunogenicity and tolerance of a tetravalent combined acellular pertussis vaccine given as a second booster. Vaccine 2004, 22:1415-1422.
250. Danjou G., Silier T., Dupuy M. Comparison of DTaP-IPV vaccine with DTP-IPV (Tetracoq) vaccine administered as a second booster at 4 to 7 years of age 1997.
251. Gajdos V., Soubeyrand B., Vidor E., et al. Immunogenicity and safety of combined adsorbed low-dose diphtheria, tetanus and inactivated poliovirus vaccine versus combined diphtheria tetanus and inactivated poliovirus vaccine (REVAXIS®) versus combined diphtheria, tetanus and inactivated poliovirus vaccine (DT Polio®) given as a booster dose at 6 years of age. Hum Vaccine 2011, 7:1-8.
252. Sanofi Pasteur, Study A3R22. Data in file.
253. Sanofi Pasteur, Study TD517. Data in file.
254. Guerra F., Blatter M.A., Greenberg D., et al. Safety and immunogenicity of a pentavalent vaccine compared with separate administration of licensed equivalent vaccines in US infants and toddlers and persistence of antibodies before a pre-school booster dose: a randomized, clinical trial. Pediatrics 2009, 123:301-312.
255. Zinke M., Disselhoff J., Gartner B., et al. Immunological persistence in 4-6 and 7-9 year olds previously vaccinated in infancy with hexavalent DTPa-HBV-IPV/Hib. Hum Vaccin 2010, 6:189-193.
256. Rennels M.B. Need for polio boosters after two years. Vaccine 2009, 27:179-180.
257. Salk J. Persistence of immunity after administration of formalin-treated poliovirus vaccine. Lancet 1960, 2:715-723.
258. Salk J. Are booster doses of poliovirus vaccine necessary?. Vaccine 1990, 8:419-420.
259. Salk D., van Wezel A.L.S.J. Induction of long-term immunity to paralytic poliomyelitis by use of non-infectious vaccine. Lancet 1984, 1317-1321.
260. Abbink F., Buisman A.M., Doornbos G., et al. Poliovirus-specific memory immunity in seronegative elderly people does not protect against virus excretion. J Infect Dis 2005, 191:990-999.
261. Sanofi Pasteur, Regulatory Department. Data in file.
262. Wattigney W.A., Mootrey G.T., Braun M.M., et al. Surveillance for poliovirus vaccine adverse events, 1991 to 1998: impact of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine. Pediatrics 2001, 107:E83.
263. Reinert P., Boucher J., Pines E., et al. Primary and booster immunization with DTaP-IPV vaccine administered either in combination or in association with a Haemophilus influenzae type b vaccine (Act-HIB): a large scale safety study 1997, Paris.
264. Nathanson N., Langmuir A.D. The Cutter Incident. Poliomyelitis following formaldehyde-inactivated poliovirus vaccination in the United states during the spring of 1955. I. Background. Am J Hyg 1963, 78:16-28.
265. Nathanson N., Langmuir A.D. The Cutter incident. Poliomyelitis following formaldehyde-inactivated poliovirus vaccination in the United States during the Spring of 1955. II. Relationship of poliomyelitis to Cutter vaccine. 1963. Am J Epidemiol 1995, 142:109-140.
266. Offit P.A. The Cutter Incident: How America's First Polio Vaccine Led to the Growing Vaccine Crisis 2005, Yale University Press, New Haven.
267. Plotkin S.A. Inactivated polio vaccine for the United States: a missed vaccination opportunity. Pediatr Infect Dis J 1995, 14:835-839.
268. Butel J.S., Lednicky J.A. Cell and molecular biology of simian virus 40: implications for human infections and disease. J Natl Cancer Inst 1999, 91:119-134.
269. Vilchez R.A., Madden C.R., Kozinetz C.A., et al. Association between simian virus 40 and non-Hodgkin lymphoma. Lancet 2002, 359:817-823.
270. Shivapurkar N., Harada K., Reddy J., et al. Presence of simian virus 40 DNA sequences in human lymphomas. Lancet 2002, 359:851-852.
271. Dang-Tan T., Mahmud S.M., Puntoni R., et al. Polio vaccines, Simian Virus 40, and human cancer: the epidemiologic evidence for a causal association. Oncogene 2004, 23:6535-6540.
272. Poulin D.L., De Caprio J.A. Is there a role for SV40 in human cancer?. J Clin Oncol 2006, 24:4356-4365.
273. Schattner A., Ben Chetrit E., Schmilovitz H. Poliovaccines and the course of systemic lupus erythematosus-a retrospective study of 73 patients. Vaccine 1992, 10:98-100.
274. CDC. Immunization schedules,. (Accessed November 2011). http://www.cdc.gov/vaccines/recs/schedules/default.htm.
275. Prevots D.R., Burr R.K., Sutter R.W., et al. Poliomyelitis prevention in the United States. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2000, 49:1-22.
276. WHO/UNICEF Joint Reporting Form,. (Accessed November 2011). http://www.who.int/immunization_monitoring/data/schedule_data.xls.
277. Plotkin S.A. Developed countries should use inactivated polio vaccine for the prevention of poliomyelitis. Rev Med Virol 1997, 7:75-81.
278. Centers for Disease Control and Prevention Poliomyelitis prevention in the United States: updated recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2000, 49(No. RR-5).
279. Bulletin épidémilogique Hebdomadaire (BEH). (Accessed November 2011). http://www.invs.sante.fr/beh/2010/14_15/beh_14_15.pdf.
280. Public Health Agency of Canada. (Accessed November 2011). http://www.phac-aspc.gc.ca/im/is-cv/index-eng.php#b.
281. Sutter R.W., Prevots D.R. Vaccine-associated paralytic poliomyelitis among immunodeficient persons. Infect Med 1994, 426:438.
282. Bottiger M. The elimination of polio in the Scandinavian countries. Public Health Rev 1993, 21:27-33.
283. Bottiger M., Mellin P., Romanus V., et al. Epidemiological events surrounding a paralytic case of poliomyelitis in Sweden. Bull World Health Organ 1979, 57:99-103.
284. Hovi T., Cantell K., Huovilainen A., et al. Outbreak of paralytic poliomyelitis in Finland: widespread circulation of antigenically altered poliovirus type 3 in a vaccinated population. Lancet 1986, 1:1427-1432.
285. Lapinleimu K. Elimination of poliomyelitis in Finland. Rev Infect Dis 1984, 6(Suppl. 2):S457-S460.
286. Magrath D.I., Evans D.M., Ferguson M., et al. Antigenic and molecular properties of type 3 poliovirus responsible for an outbreak of poliomyelitis in a vaccinated population. J Gen Virol 1986, 67:899-905.
287. Piirainen L., Stenvik M., Roivainen M., et al. Randomised, controlled trial with the trypsin-modified inactivated poliovirus vaccine: assessment of intestinal immunity with live challenge virus. Vaccine 1999, 17:1084-1090.
288. von Magnus H., Petersen I. Vaccination with inactivated poliovirus vaccine and oral poliovirus vaccine in Denmark. Rev Infect Dis 1984, 6(Suppl. 2):S471-S474.
289. van Wezel A.L., van Steenis G., van der Marel P., et al. Inactivated poliovirus vaccine: current production methods and new developments. Rev Infect Dis 1984, 6(Suppl. 2):S335-S340.
290. Conyn-Van Spaendonck M.A., de Melker H.E., Abbink F., et al. Immunity to poliomyelitis in the Netherlands. Am J Epidemiol 2001, 153:207-214.
291. Malvy D.J., Drucker J. Elimination of poliomyelitis in France: epidemiology and vaccine status. Public Health Rev 1993, 21:41-49.
292. Roure C., Rebiere I., Aymard M., et al. Surveillance de la poliomyelite en France. Bull Epidemiol Hebd 1993, 15:59-61.
293. Guerin N., Bregere P., Caudrelier P., et al. Neutralizing antibody response to oral poliovirus vaccine after primary immunization with inactivated poliovirus vaccine. Eur J Clin Microbiol Infect 1998, 17:815-816.
294. Drucker J. Poliomyelitis in France: epidemiology and vaccination status. Pediatr Infect Dis J 1991, 10:967-969.
295. Antona D., Guerin N. L'éradication de la poliomyelite: ou en est-on en 2010?. Bull Epidemiol Hebd 2010, 48:489-493.
296. Ministry of Health Ontario Wild-type poliovirus isolated in Hamilton. Public Health Epidemiol Rep 1996, 7:51-52.
297. ACIP Poliomyelitis prevention in the United States: Introduction of a sequential vaccination schedule of inactivated poliovirus vaccine-live attenuated poliovirus vaccine immunization schedules. MMWR 1997, 46:1-25.
298. Strebel P.M., Sutter R.W., Cochi S.L., et al. Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease. Clin Infect Dis 1992, 14:568-579.
299. Yogev R., Edwards K.M. Polio vaccination schedules in the United States: the rationale for change. Sem Ped Infect Dis 1999, 10:249-257.
300. Kolasa M.S., Desai S.N., Bisgard K.M., et al. Impact of the sequential poliovirus immunization schedule: a demonstration project. Am J Prev Med 2000, 18:140-145.
301. Lakhiani C.N., Vivier P.M., Alario A.J., et al. Analysis of the transition from oral polio vaccine to inactivated polio vaccine for primary immunization in a hospital-based primary care practice. Pediatr Infect Dis J 2000, 19:575-576.
302. Lieu T.A., Davis R.L., Capra A.M., et al. Variation in clinician recommendations for multiple injections during adoption of inactivated polio vaccine. Pediatrics 2001, 107:E49.
303. Eskola J., Dagan R. 2000, AvP study PNF35. Data in file.
304. Lasch E.E., Abed Y., Abdulla K., et al. Successful results of a program combining live and inactivated poliovirus vaccines to control poliomyelitis in Gaza. Rev Infect Dis 1984, 6(Suppl. 2):S467-S470.
305. Swartz T.A., Ben Porath E., Kanaaneh H., et al. Comparison of inactivated poliovirus vaccine and oral poliovirus vaccine programs in Israel. Rev Infect Dis 1984, 6(Suppl. 2):S556-S561.
306. Linder N., Taushtein I., Handsher R., et al. Placental transfer of maternal poliovirus antibodies in full-term and pre-term infants. Vaccine 1998, 16:236-239.
307. Slater P.E., Orenstein W.A., Morag A., et al. Poliomyelitis outbreak in Israel in 1988: a report with two commentaries. Lancet 1990, 335:1192-1195.
308. Fine P.E. Polio: measuring the protection that matters most. J Infect Dis 2009, 200:673-675.
309. Tucker A.W., Isaacs D., Burgess M. Cost-effectiveness analysis of changing from live oral poliovirus vaccine to inactivated poliovirus vaccine in Australia. Aust N Z J Public Health 2001, 25:411-416.
310. Global Post-eradication IPV Supply and Demand Assessment: Integraded Findings,. (Accessed November 2011). http://www.oliverwyman.com/ow/pdf_files/Post-EradicationIPVSupplyDemandMar09.pdf.
311. Khan M.M. Economics of polio vaccination in the post-eradication era: should OPV-using countries adopt IPV?. Vaccine 2008, 26:2034-2040.
312. WHO Meeting of the Strategic Advisory Group of Experts on immunization, April 2011-Conclusions and recommendations. Wkly Epidemiol Rec 2011, 86:205-220.
313. WHO Polio vaccines and polio immunization in the pre-eradication era: WHO position paper. Wkly Epidemiol Rec 2010, 85:213-228.
314. Conclusion and Recommendations of the Polio Research Committee (PRC) November 10-11, 2009, Geneva, (Accessed November 2011). http://www.polioeradication.org/Portals/0/Document/Resources/091111_Recommendation_PRC_v6.pdf.
315. Independent Monitoring Board of the Global Polio Eradication Initiative,. http://www.polioeradication.org/Portals/0/Document/Data&Monitoring/IMB_Reports/IMB_Report_April2011.pdf.
316. John T.J. Immunisation against polioviruses in developing countries. Rev Med Virol 1993, 3:149-160.
317. Hull H.F., Aylward R.B. Ending polio immunization. Science 1997, 277:780. [see comments].
318. John T.J. Anomalous observations on IPV and OPV vaccination. Dev Biol (Basel) 2001, 105:197-208.
319. The Global Polio Eradication Initiative. (Accessed November 2011). http://www.polioeradication.org/Dataandmonitoring/Poliothisweek.aspx.
320. Estevrs K. Safety of oral poliomyelitis vaccine: results of a WHO enquiry. Bull World Health Organ 1988, 66:739-746.
321. John T.J. A developing country perspective on vaccine-associated paralytic poliomyelitis. Bull World Health Organ 2004, 82:53-57.
322. McBean A.M., Modlin J.F. Rationale for the sequential use of inactivated poliovirus vaccine and live attenuated poliovirus vaccine for routine poliomyelitis immunization in the United States. Pediatr Infect Dis J 1987, 6:881-887.
323. Hull H.F., Aylward R.B. Progress towards global polio eradication. Vaccine 2001, 19:4378-4384.
324. Hull H.F., Birmingham M.E., Melgaard B., et al. Progress toward global polio eradication. J Infect Dis 1997, 175(Suppl. 1):S4-S9.
325. Arita I., Nakane M., Fenner F. Public health: Is polio eradication realistic?. Science 2006, 312:852-854.
326. Aylward R.B., Sutter R.W., Heymann D.L. Policy. OPV cessation-the final step to a "polio-free" world. Science 2005, 310:625-626.
327. Kew O.M., Sutter R.W., de Gourville E.M., et al. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu Rev Microbiol 2005, 59:587-635.
328. Bonu S., Rani M., Baker T.D. The impact of the national polio immunization campaign on levels and equity in immunization coverage: evidence from rural North India. Soc Sci Med 2003, 57:1807-1819.
329. Phadke A., Kale A. The mirage of polio eradication. Natl Med J India 2004, 17:282.
330. Sharma D.C. Indian experts favour IPV to eradicate polio. Lancet 2003, 362:1292.
331. Vaccines and biologicals Report of the interim meeting of the technical consultative group (TCG) on the global eradication of poliomyelitis, Geneva, November 9-11, 2002 2003, World Health Organization, Geneva.
332. CDC Brief report: Conclusions and recommendations of the Advisory Committee on Poliomyelitis Eradication-Geneva, Switzerland, October 2005. MMWR Morb Mortal Wkly Rep 2005, 54:1186-1188.
333. Heymann D.L., Sutter R.W., Aylward R.B. A global call for new polio vaccines. Nature 2005, 434:699-700.
334. Henderson D.A. Countering the posteradication threat of smallpox and polio. Clin Infect Dis 2002, 34:79-83.
335. John T.J. The final stages of the global eradication of polio. N Engl J Med 2000, 343:806-807.
336. WHO. Vaccines and Immunization, (Accessed November 2011). http://www.euro.who.int/en/what-we-do/health-topics/diseases-and-conditions/poliomyelitis/publications/2010/who-epidemiological-brief-10-importation-of-wild-poliovirus-and-response-measures-in-the-european-region.
337. Diamond B. Global polio campaign doomed to fail, experts warn. Nat Med 2005, 11:1260.
338. Agol V.I., Chumakov K., Ehrenfeld E., et al. Don't drop current vaccine until we have new ones. Nature 2005, 435:881.
339. Georgescu M.M., Delpeyroux F., Tardy-Panit M., et al. High diversity of poliovirus strains isolated from the central nervous system from patients with vaccine-associated paralytic poliomyelitis. J Virol 1994, 68:8089-8101.
340. Dove A.W., Racaniello V.R. The polio eradication effort: should vaccine eradication be next?. Science 1997, 277:779-780. [see comments].
341. CDC Prolonged poliovirus excretion in an immunodeficient person with vaccine-associated paralytic poliomyelitis. MMWR Morb Mortal Wkly Rep 1997, 46:641-643.
342. Guillot S., Caro V., Cuervo N., et al. Natural genetic exchanges between vaccine and wild poliovirus strains in humans. J Virol 2000, 74:8434-8443.
343. Kew O., Morris-Glasgow V., Landaverde M., et al. Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus. Science 2002, 296:356-359.
344. Prevention of poliomyelitis: recommendations for use of only inactivated poliovirus vaccine for routine immunization. Committee on Infectious Diseases. American Academy of Pediatrics. Pediatrics 1999, 104:1404-1406.
345. Racaniello V.R. It is too early to stop polio vaccination. Bull World Health Organ 2000, 78:359-360.
346. Schoub B.D. The risks of stopping vaccination: perspectives from the developing world. Bull World Health Organ 2000, 78:360-361.
347. Fine P.E. Gaps in our knowledge about transmission of vaccine-derived polioviruses. Bull World Health Organ 2000, 78:358-359.
348. Introduction of inactivated poliovirus vaccine into oral poliovirus vaccine-using countries. Wkly Epidemiol Rec 2003, 78:241-250.
349. Kimman T.Y., Book N. The polio eradication effort has been a great success-let's finish it and replace it with something even better. Lancet Infect Dis 2006, 6(10):675-678.